A Novel Synthetic Receptor-Based Immunoassay for Influenza Vaccine Quantification

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hashem, Anwar M ^a,b,f   Gravel, Caroline ^a   Farnsworth, Aaron ^a   Zou, Wei ^c   Lemieux, Michelle ^a   Xu, Kangwei ^d   Li, Changgui ^d   Wang, Junzhi ^d   Goneau, Marie France ^c   Merziotis, Maria ^c   He, Runtao ^e   Gilbert, Michel ^c   Li, Xuguang ^a,f  

^a HEALTH CANADA   (Canada)

^b Aziz University   (Saudi Arabia)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2,3 SIALYLLACTOSIDE RECEPTOR; ALPHA 2,3 SIALYLTRANSFERASE; ALPHA 2,6 SIALYLLACTOSIDE RECEPTOR; ALPHA 2,6 SIALYLTRANSFERASE; AZIDE; INFLUENZA VACCINE; N ACETYLNEURAMINIC ACID 2,3 LACTOSE; N ACETYLNEURAMINIC ACID 2,6 LACTOSE; N ACETYLNEURAMINIC ACID DERIVATIVE; SERUM ALBUMIN; SIALIC ACID; SIALYLTRANSFERASE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS RECEPTOR;

ACCURACY; ANTIGEN SPECIFICITY; ARTICLE; AVIAN INFLUENZA VIRUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNODIFFUSION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; LIMIT OF QUANTITATION; LINKAGE ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PH MEASUREMENT; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIALYLATION; TEMPERATURE MEASUREMENT;

ANIMALS; ANTIGENS, VIRAL; AZIDES; BIRDS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSIDES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNODIFFUSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; N-ACETYLNEURAMINIC ACID; PROTEIN DENATURATION; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; SIALYLTRANSFERASES; SPECIES SPECIFICITY;

EID: 84873720921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055428     Document Type: Article

References (61)

1. Zambon MC, (1999) Epidemiology and pathogenesis of influenza. J Antimicrob Chemother 44: 3-9.
2. Poland GA, Rottinghaus ST, Jacobson RM, (2001) Influenza vaccines: a review and rationale for use in developed and underdeveloped countries. Vaccine 19(17-19): 2216-2220 doi:10.1016/S0264-410X(00)00448-5.
3. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, et al. (2006) Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55: 1-42.
4. Du L, Zhou Y, Jiang S, (2010) Research and development of universal influenza vaccines. Microbes Infect 12(4): 280-286 doi:10.1016/j.micinf.2010.01.001.
5. Schulman JL, Khakpour M, Kilbourne ED, (1986) Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2(8): 778-786.
6. Rott R, Becht H, Orlich M, (1974) The significance of influenza virus neuraminidase in immunity. J Gen Virol 22(1): 35-41.
7. Johansson BE, Grajower B, Kilbourne ED, (1993) Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11(10): 1037-1039.
8. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4(2): e59 doi:10.1371/journal.pmed.0040059.
9. Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, et al. (2009) Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 199(11): 1629-1637 doi:10.1086/598954.
10. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, et al. (2010) Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Vaccine 28(36): 5774-5784 doi:10.1016/j.vaccine.2010.06.075.
11. Marcelin G, DuBois R, Rubrum A, Russell C, McElhaney J, et al. (2010) A contributing role for anti-neuraminidase antibodies. PloS one 6(10): e26335. doi:10.1371/journal.pone.0026335.
12. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312(5772): 404-410 doi:10.1126/science.1124513.
13. Lindstrom SE, Hiromoto Y, Nishimura H, Saito T, Nerome R, et al. (1999) Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. J Virol 73(5): 4413-4426.
14. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y, (1992) Evolution and Ecology of Influenza A Viruses. Microbiol Rev 56(1): 152-179.
15. Connor RJ, Kawaoka Y, Webster RG, Paulson JC, (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205: 17-23.
16. Hannoun C, Megas F, Piercy J, (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103(1-2): 133-138.
17. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57: 1-60.
18. Wood JM, Schild GC, Neuman RW, Seagroatt V, (1977) An improved single radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5(3): 237-247.
19. Hardy S, Eichelberger M, Griffiths E, Weir JP, Wood D, et al. (2011) Confronting the next pandemic - Workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010. Influenza Other Respi Viruses 5(6): 438-442 doi:10.1111/j.1750-2659.2011.00250.x.
20. Williams MS, (1993) Single radial immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 37(3-4): 253-262.
21. Wood JM, Dunleavy U, Newman RW, Riley AM, Robertson JS, et al. (1999) The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 98: 183-188.
22. La MontagneJR, Noble GR, Quinnan GV, Curlin GT, Blackwelder WC, et al. (1983) Summary of clinical trials of inactivated influenza vaccine- 1978. Rev Infect Dis 5(4): 723-736.
23. Cate TR, Couch RB, Parker D, Baxter B, (1983) Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines- 1978. Rev Infect Dis 5(4): 737-747.
24. Wright PF, Cherry JD, Foy HM, Glezen WP, Hall CB, et al. (1983) Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children - a multicentered evaluation of dosage and safety. Rev Infect Dis 5(4): 758-764.
25. Bucher DJ, Li SSL, Kehoe JM, Kilbourne ED, (1976) Chromatographic isolation of the hemagglutinin polypeptides from influenza virus vaccine and determination of their amino-terminal sequences. Proc Nat Acad Sci U S A 73(1): 238-242.
26. Phelan MA, Cohen KA, (1983) Gradient optimization principles in reversed-phase high-performance liquid chromatography and the separation of influenza virus components. J Chromatogr 266: 55-66.
27. García-Cañas V, Lorbetskie B, Girard M, (2006) Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J Chromatogr A 1123(2): 225-232 doi:10.1016/j.chroma.2006.04.003.
28. Kapteyn JC, Saidi MD, Dijkstra R, Kars C, Tjon JC, et al. (2006) Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 24(16): 3137-3144 doi:10.1016/j.vaccine.2006.01.046.
29. Kapteyn JC, Porre AM, de Rond EJ, Hessels WB, Tijms MA, et al. (2009) HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 27(9): 1468-1477 doi:10.1016/j.vaccine.2008.11.113.
30. García-Cañas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M, (2007) Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 79(8): 3164-3172 doi:10.1021/ac0621120.
31. Luna LG, Williams TL, Pirkle JL, Barr JR, (2008) Ultra performance liquid chromatography isotope dilution tandem mass spectrometry for the absolute quantification of proteins and peptides. Anal Chem 80(8): 2688-2693 doi:10.1021/ac701945h.
32. Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, et al. (2008) Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 26(2): 2510-2520 doi:10.1016/j.vaccine.2008.03.014.
33. Getie-Kebtie M, Chen D, Eichelberger M, Alterman M, (2009) Proteomics based characterization of hemagglutinins in different strains of influenza virus. Proteomics Clin Appl 3(8): 979-988 doi:10.1002/prca.200800219.
34. Creskey MC, Smith DG, Cyr TD, (2010) Strain identification of commercial influenza vaccines by mass spectrometry. Anal Biochem 406(2): 193-203 doi:10.1016/j.ab.2010.07.016.
35. Li C, Shao M, Cui X, Song Y, Li J, et al. (2010) Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 38(2): 284-289 doi:10.1016/j.biologicals.2009.12.004.
36. Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, et al. (2011) Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial. Vaccine 29(8): 1569-1575 doi:10.1016/j.vaccine.2010.12.116.
37. Chun S, Li C, Van Domselaar G, Wang J, Farnsworth A, et al. (2008) Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 26(48): 6068-6076 doi:10.1016/j.vaccine.2008.09.015.
38. Hashem AM, Van Domselaar G, Li C, Wang J, She YM, et al. (2010) Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun 403(2): 247-251 10.1016/j.bbrc.2010.11.030.
39. Hashem AM, Doyle TM, Van Domselaar G, Farnsworth A, Li C, et al. (2011) Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins and their Biological Relevance. Current Bioinformatics 6(4): 415-426.
40. Li C, Jaentschke B, Song Y, Wang J, Cyr TD, et al. (2010) A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 5(1): 14-19 doi:10.1038/nprot.2009.200.
41. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, et al. (2011) Quantitative analyses of all influenza type a viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. J Vis Exp 50 doi:10.3791/2784. Available: http://www.jove.com/details.php?id=2784.
42. Legastelois I, Chevalier M, Bernard MC, de Montfort A, Fouque M, et al. (2011) Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines. J Virol Methods 178: 129-136 doi:10.1016/j.jviromet.2011.08.027.
43. Gambaryan AS, Matrosovich MN, (1992) A solid-phase enzyme-linked assay for influenza virus receptor-binding activity. J Virol Methods 39: 111-123.
44. Luykx DM, Casteleijn MG, Jiskoot W, Westdijk D, Jongen PM, (2004) Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci 23(1): 65-75.
45. Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I, et al. (2010) Enhanced Immunogenicity of Stabilized Trimeric Soluble Influenza Hemagglutinin. PLoS ONE 5(9): e12466 doi:10.1371/journal.pone.0012466.
46. Farnsworth A, Cyr TD, Li C, Wang J, Li X, (2011) Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 29(8): 1529-1533 doi:10.1016/j.vaccine.2010.12.120.
47. Quan FS, Li ZN, Kim MC, Yang D, Compans RW, et al. (2011) Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 417(1): 196-202 doi:10.1016/j.virol.2011.05.014.
48. Bliu A, Lemieux M, Li C, Li X, Wang J, et al. (2012) Modifying the thermostability of inactivated influenza vaccines. Vaccine 30: 5506-5511 doi:10.1016/j.vaccine.2012.06.051.
49. Pukin AV, Weijers CA, van Lagen B, Wechselberger R, Sun B, et al. (2008) GM3, GM2 and GM1 mimics designed for biosensing: chemoenzymatic synthesis, target affinities and 900 MHz NMR analysis. Carbohydr Res 343(4): 636-650 doi:10.1016/j.carres.2008.01.007.
50. Kakuta Y, Okino N, Kajiwara H, Ichikawa M, Takakura Y, et al. (2008) Crystal structure of Vibrionaceae Photobacterium sp. JT-ISH-224 alpha2,6-sialyltransferase in a ternary complex with donor product CMP and acceptor substrate lactose: catalytic mechanism and substrate recognition. Glycobiology 18(1): 66-73 doi:10.1093/glycob/cwm119.
51. Tsukamoto H, Takakura Y, Mine T, Yamamoto T, (2008) Photobacterium sp. JT-ISH-224 produces two sialyltransferases, alpha-/beta-galactoside alpha2,3-sialyltransferase and beta-galactoside alpha2,6-sialyltransferase. J Biochem 143(2): 187-197 doi:10.1093/jb/mvm208.
52. Chan J, Lewis AR, Gilbert M, Karwaski MF, Bennet AJ, (2010) A direct NMR method for the measurement of competitive kinetic isotope effects. Nat Chem Biol 6(6): 405-407 doi:10.1038/nchembio.352.
53. Zou W, Borrelli S, Gilbert M, Liu T, Pon RA, et al. (2004) Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J Biol Chem 279(24): 25390-25399 doi:10.1074/jbc.M402787200.
54. Zou W, Jennings HJ, (1996) Mimics of the structural elements of Type III Group B Streptococcus capsular polysaccharide. Part II: Synthesis of a carboxylate-containing hexasaccharide with a short spacer. J Carbohydr Chem 15: 279-295 doi:10.1080/07328309608005653.
55. Hashem AM, Jaentschke B, Gravel C, Tocchi M, Doyle TM, et al. (2012) Subcutaneous immunization with recombinant adenovirus expressing influenza A nucleoprotein protects mice against lethal viral challenge. Hum Vaccin Immunother 8(4): 425-430.
56. Wood JM, Mumford J, Schild GC, Webster RG, Nicholson KG, (1986) Single-radial-immunodiffusion potency tests of inactivated influenza vaccines for use in man and animals. Dev Biol Stand 64: 169-177.
57. Vivekanand PK, Diedrich P, Hindsgaul O, (1996) Use of diethyl squarate for the coupling of oligosaccharide amines to carrier proteins and characterization of the resulting neoglycoproteins by MALDI-TOF mass spectrometry. Glycoconj J 13(2): 315-319.
58. Wang YF, Chang CF, Chi CY, Wang HC, Wang JR, et al. (2012) Characterization of glycan binding specificities of influenza B viruses with correlation with hemagglutinin genotypes and clinical features. J Med Virol 84(4): 679-685 doi:10.1002/jmv.23219.
59. White JM, Wilson IA, (1987) Anti-peptide antibodies detect steps in a protein conformational change: low-pH activation of the influenza virus hemagglutinin. J Cell Biol 105(6 Pt 2): 2887-2896.
60. Chen J, Lee KH, Steinhauer DA, Stevens DJ, Skehel JJ, et al. (1998) Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 95: 409-417 doi:10.1016/S0092-8674(00)81771-7.
61. Matrosovich MN, Gambaryan AS, Tuzikov AB, Byramova NE, Mochalova LV, et al. (1993) Probing of the receptor-binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic and natural sialosides. Virology 195: 111-121.